Clinical Trial

Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of toripalimab and anlotinib hydrochloride combined with standard chemotherapy in patients with refractory dermatofibrosarcoma protuberans (DFSP) resistant to imatinib therapy, and to provide evidence for the exploration of DFSP treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-09.
Trial Details
NCT Number NCT07646080
Lead Sponsor Yanjie Zhang, MD
Conditions Dermatofibrosarcoma Protuberans (DFSP)
Enrollment 20 participants
Start Date 2026-06-15
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-16